Fig. 2: siRNA PMP22-SQ NPs treatment normalized the motor and sensory activity of both JP18 and JP18/JY13 CMT1A mice. | Communications Biology

Fig. 2: siRNA PMP22-SQ NPs treatment normalized the motor and sensory activity of both JP18 and JP18/JY13 CMT1A mice.

From: Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A

Fig. 2

Behavioral tests performed to study the motor activity of age-matched JP18 (a) and JP18/JY13 mice (b). CMT1A mice of both strains treated with siRNA PMP22-SQ NPs showed normalization of the time taken by the mice to walk across the beam or the locotronic ladder when compared to the WT and they were significantly faster and showed stronger grip strength than mice receiving 5% dextrose or siRNA Ct-SQ NPs. c Electrophysiological analysis showed that CMAP (left panel) and sensory NCV (right panel) were normalized for both JP18 and JP18/JY13 mice treated with siRNA PMP22-SQ NPs. Data represent mean ± s.e.m. Before: represent the analysis of the data before treatment. After: is the analysis of the test performed after the end of treatment. The JP18 and JP18/JY13 mice groups were divided blindly. Asterisk represents the significance between WT B6 and other groups. Hashtag represents significance between JP18 5% dextrose and the other two groups. *,#p < 0.05; **p < 0.01, ***,###p < 0.001 using ANOVA followed by Tukey’s multiple comparison tests.

Back to article page